Nykode Therapeutics AS

kr 2.99As of Sun 8 Nov 2026, 12:00 UTC
OSL:NYKDHealthcare
Country Norway
PE (Fwd) •••
TSR 7Y CAGR (19.09%)
Div yield 33.45%
ROE (25.06%)
Biotechnology
Beta (5Y) 1.02
PE TTM —
TSR TTM 25.52%
Mkt cap kr 1.171B
ROIC (72.81%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 3.47
16.21%
295.51%
Hold 7|4|11|9|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.05
0.06
0.06
0.06
22.20%
21.93%
27.93%
24.61%
Revenue$M
146.4
143.1
138.9
138.3
6.45%
6.30%
2.49%
(1.21%)
Peers (US$123.8M)
Cap (US$)
PE
183.9M
—
Capital
TTM
5Y
10Y
Leveragex
0.637
(0.231)
(0.155)
EBIT/Intx
0.782
0.041
0.043
Own earn%
(459.82)
52.76
74.92
Sh yield%
21.87
46.09
43.19
Owners
Insiders/Inst%
9.77
73.55
Short interest%
1.04
SBC / revenue%
2.74
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
10–15
$1 testx
0.0
Incr. ROIC%
11